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Abstract
Background: Phenylketonuria (PKU) is an autosomal recessive disorder of phenylalanine metabolism. The inability
to convert phenylalanine (Phe) into tyrosine causes Phe to accumulate in the body. Adherence to a protein
restricted diet, resulting in reduced Phe levels, is essential to prevent cognitive decline. Frequent evaluation of
plasma Phe levels and, if necessary, adjustment of the diet are the mainstay of treatment. We aimed to assess
whether increased self-management of PKU patients and/or their parents is feasible and safe, by providing direct
online access to blood Phe values without immediate professional guidance.
Methods: Thirty-eight patients aged ≥ 1 year participated in a 10 month randomized controlled trial. Patients were
randomized into a study group (1) or a control group (2). Group 2 continued the usual procedure: a phone call or
e-mail by a dietician in case of a deviant Phe value. Group 1 was given a personal “My PKU” web page with a
graph of their recent and previous Phe values, online general information about the dietary treatment and the
Dutch PKU follow-up guidelines, and a message-box to contact their dietician if necessary. Phe values were
provided on “My PKU” without advice. Outcome measures were: differences in mean Phe value, percentage of
values above the recommended range and Phe sample frequency, between a 10-month pre-study period and the
study period in each group, and between the groups in both periods. Furthermore we assessed satisfaction of
patients and/or parents with the ‘My PKU’ procedure of online availability.
Results: There were no significant differences in mean Phe value, percentage of values above recommended
range or in frequency of blood spot sampling for Phe determination between the pre-study period and the study
period in each group, nor between the 2 groups during the periods. All patients and/or parents expressed a high
level of satisfaction with the new way of disease management.
Conclusions: Increased self-management in PKU by providing patients and/or parents their Phe values without
advice is feasible and safe and is highly appreciated.
Trial registration: The trial was registered with The Netherlands National Trial Register (NTR #1171) before
recruitment of patients.
Background
Phenylketonuria (PKU; MIM 261600) is an autosomal
recessive inborn error of phenylalanine metabolism caused
by a deficiency of the enzyme phenylalanine hydroxylase
(PAH; EC 1.14.16.1). Consequently phenylalanine (Phe)
cannot be converted to tyrosine and accumulates in the
body. Untreated PKU results in severely retarded mental
development and neurological sequelae. These complica-
tions can effectively be prevented with a strict and unpala-
t a b l ed i e t ,s e v e r e l yl i m i t i n gP h ei n t a k ef r o mn a t u r a l
protein and supplementing all other amino acids in a mix-
ture with vitamins and minerals [1]. Patients’ blood Phe
levels are frequently measured and dietary Phe intake is
continuously adjusted on the basis of the results to keep
Phe levels within the advised range.
The concurrent Phe level and the mean lifetime Phe
level are predictive for the cognitive outcome in patients
diagnosed by newborn screening [2]. In adults, elevated
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[3]. Although there is still controversy about the safe
upper limit of Phe levels during adult life, most current
consensus guidelines support a diet for life [4-7]. There-
fore, measurement of blood Phe levels to evaluate diet-
ary adherence and to adjust therapy, is the cornerstone
of the management of patients with PKU irrespective of
age. However, maintaining Phe levels within the advised
ranges is highly demanding and intensive dietary educa-
tion, family involvement, promotion of self-reliance and
self-efficacy are required [8]. A well-known approach to
improve compliance in chronic disorders is increased
self-management, which has gained widespread use in
conditions such as diabetes [9], anticoagulation control
[10] and hypertension [11]. Self-management appears to
be safe and improves treatment-related quality of life
[10,12]. Although little evidence exists regarding self-
management in PKU, previous reports suggest that it
might be a viable option [13] and might improve dietary
compliance [14].
In recent years patients with PKU treated in the two
study sites (AMC and LUMC) had a moderate degree of
self-management. The patients and/or parents took
blood samples at home at regular intervals and sent the
blood-spots by mail to the laboratory. Results of Phe
values were reported to the patient within a week and if
values were above the recommended range, the dietician
contacted the patient and discussed the value and poten-
tial causes. Alternatively, patients and/or parents could
contact the dietician by phone or e-mail to obtain the
results.
We hypothesized that self-management could be
enhanced in this cohort by providing each individual
patient with access to their own Phe values without inter-
ference of a professional. Such a procedure might encou-
rage patients and/or parents to take more control of their
diet or the diet of their child, in relationship to the Phe
levels. Therefore, we performed an open-labeled rando-
mized controlled trial to evaluate the safety and feasibility
of online availability of individual Phe levels to PKU
patients and/or their parents, on plasma Phe levels,
frequency of blood sampling and satisfaction.
Methods
Participants
Patients were recruited via treating physicians in the two
participating Dutch metabolic centers (AMC and
LUMC). Patients were enrolled in the study between
August 2008 and October 2008. Patients with PKU,
diagnosed by newborn screening and continuously trea-
ted with a protein restricted diet and supplementation
of amino acids, were eligible for inclusion in this study.
Both patients with classical PKU (untreated Phe level >
1000 μmol/L, Phe tolerance < 500 mg/day) as well as
with non-PKU HPA (untreated Phe level < 1000 μmol/
L, Phe tolerance > 500 mg/day) could be included
[15,16].
In order to ensure sufficient understanding in parents
and patients of the monitoring and treatment, only
patients of 1 year and up were included. Exclusion cri-
teria were no access to internet at home and pregnancy
or the wish to become pregnant in the study period.
This study was approved by the Ethical Committee of
the AMC, Amsterdam. The trial was registered with
The Netherlands National Trial Register (NTR #1171)
before recruitment of patients.
Procedure
After inclusion in the study, patients were randomized into
a study group (group 1) and a control group (group 2).
During the 10 month study period, patients in group 2
maintained their usual procedure regarding information on
Phe levels and advice on necessary dietary changes: patients
and/or parents sent in a bloodspot for measurement of
Phe. Children and/or their parents received a call by the
dietician if the value was out of the advised range. They
could also obtain their Phe value by making a telephone
call or by sending an e-mail to the dietician. Adult patients
always received their Phe value, usually by e-mail.
During the study period patients and/or parents in
group 1 were given access to a secured personal web
page on a special internet site, named ‘My PKU’.I n
patients below 18 access information was provided to the
parents. In this information letter, parents were encour-
aged to access the blood results information together
with their children. After sending in a blood spot,
patients and/or parents were alerted by an automatically
generated e-mail message if a new result was available.
Phe results were available at a fixed day of the week,
comparable to the situation in group 2. Patients and/or
parents in group 1 were not actively approached by their
dietician about the Phe values if they were outside the
recommended range. On their personal webpage patients
and/or parents could find a graph with the most recent
Phe value, clearly marked as either within or outside the
recommended range, as well as an overview of the Phe
values during the past 12 months (Figure 1). Also, there
was a direct link to the Dutch guidelines on dietary man-
agement of PKU [17], and patients and/or parents could
find information about possible causes of Phe values
below or above the recommended range and on sug-
gested actions to correct the values. In the suggested
actions to correct values to the advised range, it was
advised to increase or decrease phenylalanine intake, to
increase caloric intake or to ensure better compliance in
taking the amino acid supplements. Changes in pre-
scribed amino acid supplements were made after consul-
tation with the dietician only. Patients and/or parents
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a message in a message-box on their personal web page,
which was always answered within 3 days. Importantly,
patients and/or parents were assured that, same as
before, they were always welcome to, and were expected
to, call their treating physician or their dietician in case
of a more urgent question or problem. In addition, dur-
ing the study period Phe values were continuously moni-
tored by the treating physicians and dieticians in order to
be able to intervene timely in case of Phe values out of
range without action taken by the patient and/or the
parents.
After the study period, all patients and/or parents of
group 1 continued the ‘My PKU’ procedure of online
availability. From that time ‘My PKU’ was also offered
to the patients and/or parents of group 2.
Randomization
This was an open-labeled trial. Patients were randomly
assigned to one of the two groups: one group with
online access to the Phe values (group 1) and one con-
trol group (group 2). Randomization was performed in a
1:1 ratio by a computerized program (TENALEA
Clinical Trial Data Management System) using the
(non-deterministic) minimization method as described
by Pocock and Simon [18]. Patient factors (strata) did
not influence the allocation scheme.
Measures
T h ep r i m a r yo u t c o m em e a s u r e sw e r et h ed i f f e r e n c e si n
mean Phe values and the percentage of Phe levels above
the recommended range, between the 10 month pre-study
period and the 10 month study period, in group 1 and 2.
In addition, the differences in these primary measures
between patients in group 1 and group 2 during the 10
month pre-study period and the 10 month study period
were calculated. Because PKU patients are more vulner-
able for high Phe levels at a younger age, we performed a
subgroup analysis of group 1 for the age groups < 10 years
old and 10 years and up. Per patient the mean Phe value
in each period and the percentage of these values that
were above the recommended range were calculated, these
values were used in the different statistical analysis models.
The secondary outcome measure was the difference in
frequency of blood sampling between the 10 month pre-
study period and the 10 month study period, in group 1
Figure 1 My PKU; Phe values are in μmol/L.
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sampling between both groups in the pre-study period
and the study period was calculated. In addition, in
group 1 it was monitored whether, and within how
many hours after receiving the e-mail that a new Phe
value was available on ‘My PKU’, patients and/or par-
ents logged on to ‘My PKU’. Recommended ranges for
plasma Phe values and recommended frequency of
blood sampling per age group in the Netherlands are
listed in Table 1.
Patient satisfaction
To evaluate patient satisfaction with the procedure of
online availability of Phe values, 6 months after the study
period all patients and/or parents of group 1 were sent
an e-mail in which they were asked to respond to the two
following questions: Are you satisfied with the way of
providing Phe values via a personal webpage? Which
method of providing your Phe values do you prefer?
Statistical analysis
The Statistical Package for Social Sciences (SPSS) Win-
dows version 16.0 was used for all the analyses. To test
whether there were differences between both groups for
the parameters age, mean Phe value, sample frequency
and the percentage Phe values above the recommended
range, Mann-Whitney tests were performed. To test
whether there were differences between both study peri-
ods, within each group, Wilcoxon signed-rank tests were
performed.
Results
Participants
Sixty-eight patients, 24 adults and 44 children, were eli-
gible and were invited by letter to participate in the
study. Thirty-eight patients (11 adults) consented to par-
ticipate and were randomized to either group 1 (22
patients) or group 2 (16 patients). One patient in group
1 became pregnant after randomization and was subse-
quently excluded from the study. All other patients
completed the study. Group 1 consisted of 7 males
(33.3%) and 14 females (66.7%), with a mean age of 15.0
years (SD 9.5, range 1-35 years). In group 2, 7 males
(43.8%) and 9 females (56.2%) were included with a
mean age of 10.9 years (SD 8.6, range 1-28 years). Both
groups were comparable for age and sex. Group 1 con-
sisted of 16 patients with classic PKU and 5 with non-
PKU HPA. In group 2, 9 patients with classic PKU and
7 patients with non-PKU HPA were included. The
group of patients who did not participate in the study
did not differ significantly from the study group for the
parameters age and sex.
Phe values
T h em e d i a na n dt h er a n g eo fP h ev a l u e sa n dt h ep e r -
centage of Phe values above the recommended range in
the pre-study period and the study period for both
groups are reported in Table 2. One adult patient did
not send in any bloodspot, neither in the pre-study per-
iod nor in the study period. For this reason the patient
is not included in Figure 2 and was excluded from the
statistical evaluation of the Phe values but was included
in the analysis of the sample frequency.
In group 1 there was no statistically significant differ-
ence between the pre-study mean Phe value and the
m e a nP h ev a l u ed u r i n gt h es t u d yp e r i o d .I n d i v i d u a l
mean Phe values in both periods are depicted in Figure
2. Patients in group 2 also demonstrated no significant
change in mean Phe levels between the pre-study period
and the study period. No significant difference was
found between the mean Phe values of group 1 and 2 in
the pre study period (p = 0.78) or in the study period (p
= 0.82). The percentages of Phe values above the recom-
mended range, taking into account the ranges for age
groups, between the pre-study period and the study per-
iod did not differ in either of the groups. Furthermore,
the percentages of Phe values above the recommended
range were comparable between both groups in the pre-
study period (p = 0.83) and in the study period (p =
0.79). Group 1 subgroup analysis for the age groups <
10 years and 10 years and up showed no significant dif-
ferences between the pre-study period and the study
period in mean Phe value and percentage Phe values
above the recommended range (Table 2).
After receiving the e-mail that a new Phe value was
available on the site, patients and/or their parents logged
in to their webpage within 12 hours in 163 of the total
of 201 Phe values (81%). After 48 hours 172 of the 201
Phe values were checked (88%). Only 11 Phe values
(5.5%) were not viewed by the patients and/or parents
before a new Phe value was entered. One patient did
not check 4 Phe values, 7 patients did not check one
value each. In 9 out of these 11 cases, patients had an
appointment with the dietician on the day the new
result was available, and the dietician had provided
them with their Phe value.
Table 1 Recommended ranges for plasma Phe values and
frequency of blood sampling in the Netherlands
Age Plasma Phe (μmol/L) Blood sampling
First year 120-360 weekly
1-4 120-360 every other week
4-12 120-360 monthly
12-15 120-600 monthly
> 15 120-600 monthly
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Results are listed in Table 3. Neither in group 1 nor in
group 2 a difference in the frequency of blood sampling
at home was demonstrated between the pre-study per-
iod and the study period. Because of differences in
recommended frequency of sending bloodspots, the age
group of 4 years and older was analyzed separately,
demonstrating no significant differences between both
periods. The group aged 1-4 years old consisted of only
4 patients and therefore statistical analysis was not per-
formed on the sample frequency of this group.
Furthermore in both the pre-study period and the
study period the mean sample frequency of both groups
was comparable. Separate analysis of the age group 4
years and older showed that again group 1 and 2 were
comparable in both the pre-study period (p = 0.74) as
well as in the study period (p = 0.84).
Patient satisfaction
All 22 patients and/or their parents of group 1, who
were given online availability of their Phe values,
responded to our questions on patient satisfaction. All
reacted highly positive to the question if they were satis-
fied with the way of providing Phe levels via a personal
webpage. The advantages of this system mentioned by
the patients and/or parents were the fast and reliable
availability of the results, regardless of values being
within or above the recommended range, and the rela-
tively direct contact with the dietician through the mes-
sage-box. Furthermore patients and/or parents judged
Table 2 Median Phe values (range) and % Phe values above recommended range
Measurement Pre-study Study P-value
(pre-study vs study)
Group 1 Median Phe value (μmol/L) 336 (198-1330) 408 (200-1438) 0.093
Group 1 % Phe values above rec. range 44% 49% 0.13
Group 1
< 10 years
Median Phe value (μmol/L) 273 (198-298) 295 (200-317) 0.46
% Phe values above rec. range 15% 19% 0.35
Group 1
≥ 10 years
Median Phe value (μmol/L) 599 (231-1330) 615 (271-1438) 0.16
% Phe values above rec. range 57% 63% 0.16
Group 2 Median Phe value (μmol/L) 366 (144-1201) 381(173-1367) 0.96
Group 2 % Phe values above rec. range 48% 52% 0.40
Group 1 = online availability (n = 20).
Group 2 = usual procedure (n = 16).
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Figure 2 Individual mean Phe values in the pre-study period and study period.
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graph positively. All patients and/or parents preferred
the new way of providing Phe values.
Discussion
This is the first randomized controlled trial evaluating
the effect of increased self-management on plasma Phe
levels and frequency of blood sampling in patients with
PKU.
As Phe levels, lifetime and concurrent, are the most
important determinants for the cognitive outcome of
patients with PKU the main issue in this study was to
assess the safety and feasibility of the increased self
management for the patients and/or their parents. Our
results clearly demonstrate that the increased self man-
agement does not negatively affect the mean Phe value,
the percentage of Phe values outside the recommended
range, or the sample frequency. These results partially
confirm the outcome of an uncontrolled study in which
a comparable way of increased self-management was
investigated. In this 6 month study, patients themselves
decided on frequency of blood sampling and adjust-
ments of their diet after the Phe results were provided
to them without interpretation or advice. The results
demonstrated a higher mean Phe value but a stable per-
centage of samples above the recommended range dur-
ing self management [13].
In the evaluation of group 1 as a whole, there was a no
statistical difference in mean Phe levels between the
study periods. However, we did find a trend (p 0.093)
that Phe levels increased during online access. This may
be explained by the fact that 4 patients became 12 years
old during the study. At the age of 12, according to the
Dutch guidelines, the recommended range is raised from
360 μmol/L to 600 μmol/L and usually the patients will
increase the Phe intake and the level rises around or just
before the 12
th birthday. This hypothesis was confirmed
by the fact that in subgroup analysis of patients below 10
the trend of increasing Phe levels was not found. As very
few patients below age 4 were included in the study, and
because this is a vulnerable age for high Phe levels, future
studies are warranted for this particular age group.
In PKU, the determinants of compliance include the
frequency of taking blood samples, the mean Phe value
and the percentage of Phe levels above the recom-
mended range. The relatively high percentage of the Phe
values above the recommended range during both study
periods in both groups is comparable to results from
other studies [13,19,20].
While compliance did not decrease during the inter-
vention period, we did not demonstrate the increase of
compliance that might be expected from increased self-
management [14]. Possibly it may take longer than the
10 month study period to incorporate the new approach
into the daily practice of the patients and/or their par-
ents and to develop a full understanding of the relation-
ship of Phe values to food intake and illness in this
setting.
In other chronic disorders the quality of life (QoL) of
patients has been reported to improve following self man-
agement interventions [10,21]. Hypotheses for this
improvement are enhanced self-efficacy [22-24] and
increased confidence and control resulting from a better
education and understanding of their illness. Because no
PKU specific QoL questionnaires exist and generic ques-
tionnaires have been proven not to detect abnormalities in
PKU patients, QoL has not been evaluated in this study.
Parents and/or parents, without exception, preferred
the new approach of providing Phe values and appre-
ciated the direct availability of their own Phe values, the
overview of the past values and the possibility to have a
relatively direct contact with the dietician. Patients and/
or parents interest in a more direct availability of Phe
values was manifested by the high percentage of Phe
values, checked within 12 hours after reporting on their
“My PKU” web page. The new approach enables patients
and/or their parents to make their own decisions about
when to take blood samples and how to adjust the diet.
Thereby it provides patients and/or parents more control
on their own disease and less interference with their per-
sonal lifestyle. Remarkably, using the message-box espe-
cially adolescents provided more information on their
dietary habits and asked more questions than during the
outpatient visits. Possibly, this means of communication
which this age group is highly accustomed to, is more
comfortable for them than a personal discussion.
Furthermore, the message-box is increasingly used by
treating physicians to record issues and plans discussed
during the outpatient visits, so that the patient and/or
parents have the possibility to check it at home anytime.
Conclusion
This randomized controlled trial is the first to demon-
strate that increased self-management in PKU patients
Table 3 Median sample frequency (range) in 10 months
Sample
frequency
Pre-study
Sample
frequency
Study
P-value
(pre-study vs
study)
Group 1 total 8.00 (0-29) 8.00 (0-23) 0.43
Group 1 ≥ 4
years
7.50 (0-17) 8.00 (0-23) 0.14
Group 2 total 7.50 (2-14) 8.00 (1-21) 0.36
Group 2 ≥ 4
years
6.00 (2-14) 7.00 (1-21) 0.31
Group 1 = online availability (n = 21).
Group 2 = usual procedure (n = 16).
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feasible, safe method and is highly appreciated.
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